Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure

Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition

Luzhou Xing, Zhenpeng Dai, Ali Jabbari et al. · Nature Medicine · 2014 · 953 citations · Full text

Medicine, Dermatology, Immunology +16

CXCL10 Is Critical for the Progression and Maintenance of Depigmentation in a Mouse Model of Vitiligo

Mehdi Rashighi, Priti Agarwal, Jillian M. Richmond et al. · Science Translational Medicine · 2014 · 489 citations

Life Sciences, Immunology, Molecular Biology +8

Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata

Milène K. Crispin, Justin Ko, Brittany G. Craiglow et al. · JCI Insight · 2016 · 344 citations · Full text

Medicine, Dermatology, Pharmacology +11

Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients

Lucy Liu, Brittany G. Craiglow, Feng Dai et al. · Journal of the American Academy of Dermatology · 2016 · 342 citations

Medicine, Dermatology, Pharmacotherapy +6

Tofacitinib Citrate for the Treatment of Vitiligo

Brittany G. Craiglow, Brett King · JAMA Dermatology · 2015 · 256 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12